Lonial S et al. Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments. ASH 2025;Abstract 12045.

Mateos M-V et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients with relapsed refractory multiple myeloma (RRMM): Results of MajesTEC-3. ASH 2025;Abstract LBA-6.

Quach H et al. Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. ASH 2025;Abstract 7278.

Sim S et al. Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14). ASH 2025;Abstract 7320.

Usmani S et al. Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the phase 1 DREAMM-9 study. ASH 2025;Abstract 13646.